John Leaman
2021 - IMPEL PHARMACEUTICALS
In 2021, John Leaman earned a total compensation of $2.1M as Chief Financial & Business Officer at IMPEL PHARMACEUTICALS, a 283% increase compared to previous year.
Compensation breakdown
| Bonus | $300,000 |
|---|---|
| Non-Equity Incentive Plan | $230,000 |
| Option Awards | $529,300 |
| Salary | $434,365 |
| Stock Awards | $569,151 |
| Total | $2,062,816 |
Leaman received $569.2K in stock awards, accounting for 28% of the total pay in 2021.
Leaman also received $300K in bonus, $230K in non-equity incentive plan, $529.3K in option awards and $434.4K in salary.
Rankings
In 2021, John Leaman's compensation ranked 5,933rd out of 12,405 executives tracked by ExecPay. In other words, Leaman earned more than 52.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,933 out of 12,405 | 52nd |
Division Manufacturing | 2,509 out of 5,494 | 54th |
Major group Chemicals And Allied Products | 1,092 out of 2,369 | 54th |
Industry group Drugs | 971 out of 2,090 | 54th |
Industry Pharmaceutical Preparations | 700 out of 1,537 | 55th |
Source: SEC filing on April 26, 2022.
Leaman's colleagues
We found two more compensation records of executives who worked with John Leaman at IMPEL PHARMACEUTICALS in 2021.